When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Huntington disease

  • Overview
  • Theory
  • Diagnosis
  • Management
  • Follow up
  • Resources
Last reviewed: 6 Apr 2025
Last updated: 22 Nov 2022

Summary

Definition

History and exam

Key diagnostic factors

  • positive family history of Huntington disease
  • known expansion of the CAG repeat length at the N-terminal end of the huntingtin gene
  • impaired work or school performance
  • personality change
  • irritability and impulsivity
  • chorea
  • twitching or restlessness
  • loss of coordination
  • deficit in fine motor coordination
  • slowed rapid (saccadic) eye movements
  • motor impersistence
  • impaired tandem walking
Full details

Other diagnostic factors

  • concentration impairment/task anxiety or apathy
  • cognitive decline relative to spouse/siblings
  • changes in personal habits/hygiene
  • disinhibition or unusually anxious behavior
  • depression, obsessions, and compulsions
Full details

Risk factors

  • expansion of the CAG repeat length at the N-terminal end of the huntingtin gene
  • other genetic factors
  • family history
Full details

Diagnostic tests

1st tests to order

  • no initial tests
Full details

Tests to consider

  • CAG repeat testing
  • MRI or CT scan
Full details

Treatment algorithm

ONGOING

all patients

Contributors

Authors

Mitsuko Nakajima, MD

Clinical Research Fellow

Huntington's Disease Centre

Queen Square

Institute of Neurology

Department of Neurodegenerative Disease

Russell Square House

London

UK

Disclosures

MN declares no competing interests.

Acknowledgements

Dr Mitsuko Nakajima would like to gratefully acknowledge Dr Peter McColgan, Dr Sarah Tabrizi, Dr David Craufurd, Dr Marianne Novak, and Dr Francis Walker, previous contributors to this topic.

Disclosures

FW declared that he had no competing interests. MN is an author of a reference cited in this topic. DC has received fees for advisory board membership from Hoffmann-La Roche Ltd. SJT has received grant funding for her research from CHDI Foundation, the BBSRC, Dementia and Neurodegenerative Disease Network UK, European Huntington’s Disease Network, Huntington’s Disease Association of the UK, the Medical Research Council UK, Takeda Pharmaceuticals, the UCL/UCLH Biomedical Research Center, and the Wellcome Trust. SJT has been on advisory boards or had consultancies with F. Hoffmann-La Roche Ltd, Ixico Technologies, Shire Human Genetic Therapies, Takeda Pharmaceuticals International, and TEVA Pharmaceuticals; all honoraria for these consultancies and advisory boards were paid to UCL. Through the offices of UCL Consultants Ltd, a wholly owned subsidiary of UCL, SJT has undertaken consultancy services for F. Hoffmann-La Roche Ltd and GSK. ST is also an author of references cited in this topic PM declared that he had no competing interests.

Peer reviewers

Adrian Priesol, MD, FRCPC

Instructor

Massachusetts Eye and Ear Infirmary

Harvard Medical School

Boston

MA

Disclosures

AP declares that he has no competing interests.

Tiago Mestre, MD, MSc

Resident Neurology

Neurological Clinical Research Unit

Institute of Molecular Medicine

Lisbon

Portugal

Disclosures

TM declares that he has no competing interests.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Walker FO. Huntington's disease. Lancet. 2007 Jan 20;369(9557):218-28. Abstract

Hayden MR. Huntington's chorea. New York, NY: Springer; 1981.

Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington's disease. Mov Disord. 2008 Aug 15;23(11):1491-504. Abstract

Bonelli RM, Hofmann P. A systematic review of the treatment studies in Huntington's disease since 1990. Expert Opin Pharmacother. 2007 Feb;8(2):141-53. Abstract

Novak MJ, Tabrizi SJ. Huntington's disease. BMJ. 2010 Jun 30;340:c3109. Abstract

Fasano A, Bentivoglio AR. Tetrabenazine. Expert Opin Pharmacother. 2009 Dec;10(17):2883-96. Abstract

Quinn L, Kegelmeyer D, Kloos A, et al. Clinical recommendations to guide physical therapy practice for Huntington disease. Neurology. 2020 Feb 4;94(5):217-28.Full text  Abstract

Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des. 2006;12(21):2701-20. Abstract

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

  • Differentials

    • Tardive dyskinesia
    • Dentatorubro-pallidoluysian atrophy (DRPLA)
    • Neuroacanthocytosis
    More Differentials

  • Guidelines

    • Clinical guidance in neuropalliative care: an AAN position statement
    • Clinical recommendations to guide physical therapy practice for Huntington disease
    More Guidelines

  • Patient information

    Depression in adults

    Huntington’s disease

    More Patient information
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer